Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 535

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission

Open access
Cooke, Graham S, Andrieux-Meyer, Isabelle, Applegate, Tanya L, Atun, Rifat, Burry, Jessica R, Cheinquer, Hugo, Dusheiko, Geoff, Feld, Jordan J, Gore, Charles, Griswold, Max G, Hamid, Saeed, Hellard, Margaret E, Hou, JinLin, Howell, Jess, Jia, Jidong, Kravchenko, Natalia, Lazarus, Jeffrey V, Lemoine, Maud, Lesi, Olufunmilayo A, Maistat, Liudmyla, McMahon, Brian J, Razavi, Homie, Roberts, Teri, Simmons, Bryony, Sonderup, Mark W, Spearman, C Wendy, Taylor, Bridie E, Thomas, David L, Waked, Imam, Ward, John W, Wiktor, Stefan Z, Abdo, Ayman, Aggarwal, Rakesh, Aghemo, Alessio, Al-Judaibi, Bandar, Al Mahtab, Mamun, Altaf, Arshad, Ameen, Zyaad, Asselah, Tarik, Baatarkkhuu, Oidov, Barber, Ella, Barnes, Eleanor, Boulet, Pascale, Burrows, Louise, Butsashvili, Maia, Chan, Erica, Chow, Chelsea, Cowie, Ben, Cunningham, Chris, de Araujo, Alexandre, Diap, Graciela, Dore, Greg, Doyle, Joseph, Elsayed, Manal, Fajardo, Emmanuel, Gane, Ed, Getahun, Aneley, Goldberg, David, Got, Tiffany, Hickman, Matthew, Hill, Andrew, Hutchinson, Sharon, Jones, Chris, Kamili, Saleem, Khan, Amreen, Lee, Alice, Lee, Tin Yan, Malani, Jioiji, Morris, Tammy Meyers, Nayagam, Shevanthi, Njouom, Richard, Ocama, Ponsiano, Pedrana, Alisa, Peeling, Rosanna, Reddy, Amulya, Sacks, Jilian, Sarin, Shiv, Shimakawa, Yusuke, Silva, Marcela, Skala, Pavlo, Taylor-Robinson, Simon, Thompson, Alex, Thursz, Mark, Tonganibeia, Alfred, Wallace, Jack, Ward, James, Wolff, Fernando, Vickerman, Peter, Yau, Johnny·2019·The Lancet Gastroenterology & Hepatology
DOI 10.1016/s2468-1253(18)30270-x
Open this paper in CoChat — free account

Abstract

Viral hepatitis is a major public health threat and a leading cause of death worldwide. Annual mortality from viral hepatitis is similar to that of other major infectious diseases such as HIV and tuberculosis. Highly effective prevention measures and treatments have made the global elimination of viral hepatitis a realistic goal, endorsed by all WHO member states. Ambitious targets call for a global reduction in hepatitis-related mortality of 65% and a 90% reduction in new infections by 2030. This Commission draws together a wide range of expertise to appraise the current global situation and to identify priorities globally, regionally, and nationally needed to accelerate progress. We identify 20 heavily burdened countries that account for over 75% of the global burden of viral hepatitis. Key recommendations include a greater focus on national progress towards elimination with support given, if necessary, through innovative financing measures to ensure elimination programmes are fully funded by 2020. In addition to further measures to improve access to vaccination and treatment, greater attention needs to be paid to access to affordable, high-quality diagnostics if testing is to reach the levels needed to achieve elimination goals. Simplified, decentralised models of care removing requirements for specialised prescribing will be required to reach those in need, together with sustained efforts to tackle stigma and discrimination. We identify key examples of the progress that has already been made in many countries throughout the world, demonstrating that sustained and coordinated efforts can be successful in achieving the WHO elimination goals.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2468-1253(18)30270-x

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 253

  1. Fitzmaurice, 2017, Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease study, JAMA Oncol, 3, 524, 10.1001/jamaoncol.2016.5688 · DOI · Paper page
  2. El-Serag, 2012, Epidemiology of viral hepatitis and hepatocellular carcinoma, Gastroenterology, 142, 1264, 10.1053/j.gastro.2011.12.061 · DOI · Paper page
  3. Nayagam, 2016, Requirements for global elimination of hepatitis B: a modelling study, Lancet Infect Dis, 16, 1399, 10.1016/S1473-3099(16)30204-3 · DOI · Paper page
  4. Rani, 2009, Hepatitis B control by 2012 in the WHO Western Pacific region: rationale and implications, Bull World Health Organ, 87, 707, 10.2471/BLT.08.059220 · DOI · Paper page
  5. 2017, Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study, Lancet Gastroenterol Hepatol, 2, 161, 10.1016/S2468-1253(16)30181-9 · DOI · Paper page
  6. 2018, Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study, Lancet Gastroenterol Hepatol, 3, 383, 10.1016/S2468-1253(18)30056-6 · DOI · Paper page
  7. Stanaway, 2016, The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013, Lancet, 388, 1081, 10.1016/S0140-6736(16)30579-7 · DOI · Paper page
  8. de Martel, 2015, World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma, Hepatology, 62, 1190, 10.1002/hep.27969 · DOI · Paper page
  9. Perz, 2006, The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide, J Hepatol, 45, 529, 10.1016/j.jhep.2006.05.013 · DOI · Paper page
  10. Shepard, 2006, Hepatitis B virus infection: epidemiology and vaccination, Epidemiol Rev, 28, 112, 10.1093/epirev/mxj009 · DOI · Paper page
  11. Lanini, 2016, Hepatitis C: global epidemiology and strategies for control, Clin Microbiol Infect, 22, 833, 10.1016/j.cmi.2016.07.035 · DOI · Paper page
  12. Goldstein, 2005, A mathematical model to estimate global hepatitis B disease burden and vaccination impact, Int J Epidemiol, 34, 1329, 10.1093/ije/dyi206 · DOI · Paper page
  13. 2017, Hepatitis B vaccines: WHO position paper—July 2017, Wkly Epidemiol Rec, 92, 369
  14. Wiesen, 2016, Progress towards hepatitis B prevention through vaccination in the Western Pacific, 1990–2014, Vaccine, 34, 2855, 10.1016/j.vaccine.2016.03.060 · DOI · Paper page
  15. Chiang, 2013, Thirty-year outcomes of the national hepatitis B immunization programme in Taiwan, JAMA, 310, 974, 10.1001/jama.2013.276701 · DOI · Paper page
  16. Pan, 2016, Tenofovir to prevent hepatitis B transmission in mothers with high viral load, N Engl J Med, 374, 2324, 10.1056/NEJMoa1508660 · DOI · Paper page
  17. Benova, 2014, Vertical transmission of hepatitis C virus: systematic review and meta-analysis, Clin Infect Dis, 59, 765, 10.1093/cid/ciu447 · DOI · Paper page
  18. Larney, 2017, Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review, Lancet Glob Health, 5, e1208, 10.1016/S2214-109X(17)30373-X · DOI · Paper page
  19. Degenhardt, 2017, Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review, Lancet Glob Health, 5, e1192, 10.1016/S2214-109X(17)30375-3 · DOI · Paper page
  20. Jones, 2016, Problem drug use prevalence estimation revisited: heterogeneity in capture-recapture and the role of external evidence, Addiction, 111, 438, 10.1111/add.13222 · DOI
  21. Palmateer, 2014, Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data, J Viral Hepat, 21, 25, 10.1111/jvh.12117 · doi:10.1111/jvh.12117
  22. Gower, 2014, Global epidemiology and genotype distribution of the hepatitis C virus infection, J Hepatol, 61, S45, 10.1016/j.jhep.2014.07.027 · DOI · Paper page
  23. Schweitzer, 2015, Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013, Lancet, 386, 1546, 10.1016/S0140-6736(15)61412-X · DOI · Paper page
  24. Walsh, 2014, WHO guidance on the prevention of viral hepatitis B and C among people who inject drugs, Int J Drug Policy, 25, 363, 10.1016/j.drugpo.2014.01.009 · DOI
  25. Palmateer, 2010, Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews, Addiction, 105, 844, 10.1111/j.1360-0443.2009.02888.x · DOI · Paper page
  26. MacArthur, 2014, Interventions to prevent HIV and hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness, Int J Drug Policy, 25, 34, 10.1016/j.drugpo.2013.07.001 · DOI · Paper page
  27. Platt, 2017, Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs, Cochrane Database Syst Rev, 9
  28. Degenhardt, 2014, What has been achieved in HIV prevention, treatment and care for people who inject drugs, 2010–2012? A review of the six highest burden countries, Int J Drug Policy, 25, 53, 10.1016/j.drugpo.2013.08.004 · DOI · Paper page
  29. Csete, 2016, Public health and international drug policy, Lancet, 387, 1427, 10.1016/S0140-6736(16)00619-X · DOI · Paper page
  30. Scheiblauer, 2006, Evaluation of 17 CE-marked HBsAg assays with respect to clinical sensitivity, analytical sensitivity, and hepatitis B virus mutant detection, J Med Virol, 78, S66, 10.1002/jmv.20611 · doi:10.1002/jmv.20611
  31. Day, 2018, Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework, Liver Int
  32. Grebely, 2018, Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial, Lancet Gastroenterol Hepatol, 3, 153, 10.1016/S2468-1253(17)30404-1 · DOI · Paper page
  33. Midgard, 2016, Hepatitis C reinfection after sustained virological response, J Hepatol, 64, 1020, 10.1016/j.jhep.2016.01.001 · doi:10.1016/j.jhep.2016.01.001
  34. Midgard, 2016, HCV epidemiology in high-risk groups and the risk of reinfection, J Hepatol, 65, S33, 10.1016/j.jhep.2016.07.012 · DOI · Paper page
  35. Martinello, 2017, HCV reinfection incidence among individuals treated for recent infection, J Viral Hepat, 24, 359, 10.1111/jvh.12666 · DOI
  36. Vickerman, 2012, Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings, Addiction, 107, 1984, 10.1111/j.1360-0443.2012.03932.x · DOI
  37. Martin, 2013, Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programmes, and opiate substitution therapy, Clin Infect Dis, 57, S39, 10.1093/cid/cit296 · DOI · Paper page
  38. Martin, 2013, Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals, Hepatology, 58, 1598, 10.1002/hep.26431 · DOI · Paper page
  39. Martin, 2016, Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation, J Hepatol, 65, 17, 10.1016/j.jhep.2016.02.007 · DOI · Paper page
  40. Hickman, 2017, Hepatitis C virus prevention and treatment prioritization-ethical, economic and evidential dimensions of early rather than delayed treatment for people who inject drugs, Addiction, 112, 201, 10.1111/add.13521 · DOI
  41. Martin, 2015, The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention, Curr Opin HIV AIDS, 10, 374, 10.1097/COH.0000000000000179 · DOI
  42. Grebely, 2015, Recommendations for the management of hepatitis C virus infection among people who inject drugs, Int J Drug Policy, 26, 1028, 10.1016/j.drugpo.2015.07.005 · DOI · Paper page
  43. Vescio, 2008, Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis, J Epidemiol Community Health, 62, 305, 10.1136/jech.2006.051599 · DOI · Paper page
  44. Hunt, 2009, Viral hepatitis in incarcerated adults: a medical and public health concern, Am J Gastroenterol, 104, 1024, 10.1038/ajg.2008.143 · DOI
  45. Kamarulzaman, 2016, Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners, Lancet, 388, 1115, 10.1016/S0140-6736(16)30769-3 · DOI · Paper page
  46. Butler, 2004, Prisoners are at risk for hepatitis C transmission, Eur J Epidemiol, 19, 1119, 10.1007/s10654-004-1705-9 · DOI
  47. Dolan, 2010, Incidence and risk for acute hepatitis C infection during imprisonment in Australia, Eur J Epidemiol, 25, 143, 10.1007/s10654-009-9421-0 · DOI
  48. Binswanger, 2007, Release from prison— a high risk of death for former inmates, N Engl J Med, 356, 157, 10.1056/NEJMsa064115 · DOI · Paper page
  49. Koff, 1977, Contagiousness of acute hepatitis B. Secondary attack rates in household contacts, Gastroenterology, 72, 297, 10.1016/S0016-5085(77)80090-5 · DOI
  50. François, 2002, Hepatitis B vaccination: how to reach risk groups, Vaccine, 21, 1, 10.1016/S0264-410X(02)00440-1 · DOI
  51. Wang, 2012, Prevalence and factors associated with hepatitis B immunization and infection among men who have sex with men in Beijing, China, PLoS One, 7, e48219, 10.1371/journal.pone.0048219 · DOI
  52. Daley, 2009, Physician practices regarding adult hepatitis B vaccination: a national survey, Am J Prev Med, 36, 491, 10.1016/j.amepre.2009.01.037 · DOI
  53. Gorgos, 2013, Sexual transmission of viral hepatitis, Infect Dis Clin North Am, 27, 811, 10.1016/j.idc.2013.08.002 · DOI
  54. Yaphe, 2012, Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review, Sex Transm Infect, 88, 558, 10.1136/sextrans-2012-050566 · DOI · Paper page
  55. Simmons, 2016, Risk of late relapse or reinfection with hepatitis c virus after achieving a sustained virological response: a systematic review and meta-analysis, Clin Infect Dis, 62, 683, 10.1093/cid/civ948 · DOI · Paper page
  56. Boerekamps, 2018, Declining hepatitis C virus (HCV) incidence in Dutch human immunodeficiency virus-positive men who have sex with men after unrestricted access to HCV therapy, Clin Infect Dis, 66, 1360, 10.1093/cid/cix1007 · DOI · Paper page
  57. Pépin, 2014, Evolution of the global burden of viral infections from unsafe medical injections, 2000-2010, PLoS One, 9, e99677, 10.1371/journal.pone.0099677 · DOI · Paper page
  58. Khan, 2000, Unsafe injections and the transmission of hepatitis B and C in a periurban community in Pakistan, Bull World Health Organ, 78, 956
  59. Stone, 2016, The potential impact of a hepatitis C vaccine for people who inject drugs: is a vaccine needed in the age of direct-acting antivirals?, PLoS One, 11, e0156213, 10.1371/journal.pone.0156213 · doi:10.1371/journal.pone.0156213
  60. Osburn, 2010, Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection, Gastroenterology, 138, 315, 10.1053/j.gastro.2009.09.017 · DOI · Paper page
  61. Baumert, 2014, A prophylactic hepatitis C virus vaccine: a distant peak still worth climbing, J Hepatol, 61, S34, 10.1016/j.jhep.2014.09.009 · DOI
  62. Lemoine, 2016, Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study, Lancet Glob Health, 4, e559, 10.1016/S2214-109X(16)30130-9 · DOI · Paper page
  63. Nayagam, 2016, Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis, Lancet Glob Health, 4, e568, 10.1016/S2214-109X(16)30101-2 · DOI
  64. Shiffman, 2016, Universal screening for chronic hepatitis C virus, Liver Int, 36, 62, 10.1111/liv.13012 · DOI
  65. Scott, 2017, Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade, Int J Drug Policy, 47, 107, 10.1016/j.drugpo.2017.07.006 · doi:10.1016/j.drugpo.2017.07.006
  66. Morgan, 2017, Economic evaluation of HCV testing approaches in low and middle income countries, BMC Infect Dis, 17, 697, 10.1186/s12879-017-2779-9 · DOI
  67. Elsharkawy, 2017, Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: lessons from the Egyptian experience, J Hepatol, 68, 691, 10.1016/j.jhep.2017.11.034 · DOI
  68. Marshall, 2017, Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe, Lancet Gastroenterol Hepatol
  69. Elsherif, 2017, Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response, PLoS One, 12, e0178398, 10.1371/journal.pone.0178398 · DOI
  70. Sulkowski, 2017, Randomized controlled trial of cash incentives or peer mentors to improve HCV linkage and treatment among HIV/HCV coinfected persons who inject drugs: the CHAMPS study, J Hepatol, 66, S719
  71. Wade, 2016, A systematic review of community based hepatitis C treatment, BMC Infect Dis, 16, 202, 10.1186/s12879-016-1548-5 · doi:10.1186/s12879-016-1548-5
  72. Zhou, 2016, Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses, Lancet Infect Dis, 16, 1409, 10.1016/S1473-3099(16)30208-0 · DOI · Paper page
  73. Marshall, 2015, Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study, Int J Drug Policy, 26, 984, 10.1016/j.drugpo.2015.07.002 · doi:10.1016/j.drugpo.2015.07.002
  74. Shimakawa, 2018, Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa, J Hepatol, 69, 776, 10.1016/j.jhep.2018.05.024 · DOI
  75. Kanwal, 2017, Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents, Gastroenterology, 153, 996, 10.1053/j.gastro.2017.06.012 · DOI · Paper page
  76. Dore, 2018, Elimination of hepatitis C virus in Australia: laying the foundation, Infect Dis Clin North Am, 32, 269, 10.1016/j.idc.2018.02.006 · DOI
  77. Kattakuzhy, 2017, Expansion of treatment for hepatitis c virus infection by task shifting to community-based nonspecialist providers: a nonrandomized clinical trial, Ann Intern Med, 167, 311, 10.7326/M17-0118 · doi:10.7326/m17-0118
  78. Lloyd, 2013, Safety and effectiveness of a nurse-led outreach programme for assessment and treatment of chronic hepatitis C in the custodial setting, Clin Infect Dis, 56, 1078, 10.1093/cid/cis1202 · DOI
  79. Yehia, 2014, The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis, PLoS One, 9, e101554, 10.1371/journal.pone.0101554 · DOI · Paper page
  80. Mera, 2016, Identification and clinical management of persons with chronic hepatitis C virus infection—Cherokee Nation, 2012–2015, MMWR Morb Mortal Wkly Rep, 65, 461, 10.15585/mmwr.mm6518a2 · doi:10.15585/mmwr.mm6518a2
  81. Bajis, 2017, Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: a systematic review, Int J Drug Policy, 47, 34, 10.1016/j.drugpo.2017.07.002 · DOI · Paper page
  82. Hellard, 2014, The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs, Hepatology, 60, 1861, 10.1002/hep.27403 · doi:10.1002/hep.27403
  83. Lasser, 2017, A hepatitis C treatment program based in a safety-net hospital patient-centered medical home, Ann Fam Med, 15, 258, 10.1370/afm.2069 · DOI
  84. Ford, 2017, From care to cure: demonstrating a model of clinical patient navigation for hepatitis C care and treatment in high-need patients, Clin Infect Dis, 64, 685, 10.1093/cid/ciw806 · DOI
  85. Uribe, 2016, Rates of treatment eligibility in follow-up of patients with chronic hepatitis B (CHB) across various clinical settings who were initially ineligible at presentation, Dig Dis Sci, 61, 618, 10.1007/s10620-015-3982-4 · doi:10.1007/s10620-015-3982-4
  86. Lemoine, 2016, The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa, Gut, 65, 1369, 10.1136/gutjnl-2015-309260 · DOI · Paper page
  87. Peeling, 2017, The future of viral hepatitis testing: innovations in testing technologies and approaches, BMC Infect Dis, 17, 699, 10.1186/s12879-017-2775-0 · DOI
  88. Amini, 2017, Diagnostic accuracy of tests to detect hepatitis B surface antigen: a systematic review of the literature and meta-analysis, BMC Infect Dis, 17, 698, 10.1186/s12879-017-2772-3 · DOI
  89. Tang, 2017, Diagnostic accuracy of tests to detect Hepatitis C antibody: a meta-analysis and review of the literature, BMC Infect Dis, 17, 695, 10.1186/s12879-017-2773-2 · DOI
  90. Laperche, 2013, Multinational assessment of blood-borne virus testing and transfusion safety on the African continent, Transfusion, 53, 816, 10.1111/j.1537-2995.2012.03797.x · DOI
  91. Marwaha, 2014, Current testing strategies for hepatitis C virus infection in blood donors and the way forward, World J Gastroenterol, 20, 2948, 10.3748/wjg.v20.i11.2948 · doi:10.3748/wjg.v20.i11.2948
  92. Grebely, 2017, Evaluation of the Xpert HCV viral load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study, Lancet Gastroenterol Hepatol, 2, 514, 10.1016/S2468-1253(17)30075-4 · DOI
  93. Gupta, 2017, Point-of-care testing (POCT) in molecular diagnostics: performance evaluation of GeneXpert HCV RNA test in diagnosing and monitoring of HCV infection, J Clin Virol, 88, 46, 10.1016/j.jcv.2017.01.006 · DOI
  94. Iwamoto, 2018, Field evaluation of GeneXpert (Cepheid) HCV performance for RNA quantification in a genotype 1 and 6 predominant patient population in Cambodia, J Viral Hepat, 10.1016/S0168-8278(18)30863-8 · doi:10.1016/s0168-8278(18)30863-8
  95. Lamoury, 2018, Evaluation of the Xpert HCV viral load finger-stick point-of-care assay, J Infect Dis, 217, 1889, 10.1093/infdis/jiy114 · doi:10.1093/infdis/jiy114
  96. Llibre, 2018, Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus, Gut, 10.1136/gutjnl-2017-315783 · doi:10.1136/gutjnl-2017-315783
  97. Easterbrook, 2016, Who to test and how to test for chronic hepatitis C infection— 2016 WHO testing guidance for low- and middle-income countries, J Hepatol, 65, S46, 10.1016/j.jhep.2016.08.002 · DOI
  98. 2017, EASL recommendations on treatment of hepatitis C 2016, J Hepatol, 66, 153, 10.1016/j.jhep.2016.09.001 · DOI · Paper page
  99. Lange, 2017, Diagnostic accuracy of serological diagnosis of hepatitis C and B using dried spot samples (DBS): two systematic reviews and meta-analyses, BMC Infect Dis, 17, 700, 10.1186/s12879-017-2777-y · DOI
  100. Lange, 2017, Diagnostic accuracy of detection and quantification of HBV-DA and HCV-RNA using dried blood spots (DBS) samples – a systematic review and meta-analysis, BMC Infect Dis, 17, 693, 10.1186/s12879-017-2776-z · DOI
  101. van de Ven, 2015, Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus, Hepatology, 61, 1174, 10.1002/hep.27641 · doi:10.1002/hep.27641
  102. Hill, 2015, Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries, J Virus Erad, 1, 103, 10.1016/S2055-6640(20)30484-2 · DOI
  103. Thursz, 2010, Hepatitis B treatment in resource poor settings: time for action, Trop Med Int Health, 15, 2
  104. Hill, 2017, The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries, J Virus Erad, 3, 117, 10.1016/S2055-6640(20)30329-0 · DOI
  105. Hill, 2016, Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C, J Virus Erad, 2, 28, 10.1016/S2055-6640(20)30691-9 · DOI
  106. Richmond, 2018, Implementation of hepatitis C cure in Australia: one year on, J Virus Erad, 4, 115, 10.1016/S2055-6640(20)30254-5 · doi:10.1016/s2055-6640(20)30254-5
  107. Andrieux-Meyer, 2015, Disparity in market prices for hepatitis C virus direct-acting drugs, Lancet Glob Health, 3, e676, 10.1016/S2214-109X(15)00156-4 · DOI · Paper page
  108. Andrieux-Meyer, 2018, Safety and efficacy of ravidasvir plus sofosbuvir 12 weeks in noncirrhotic and 24 weeks in cirrhotic patients with hepatitis C virus genotypes 1, 2, 3 and 6: the STORM-C-1 phase II/III trial, J Hepatol, 68, S123, 10.1016/S0168-8278(18)30459-8 · doi:10.1016/s0168-8278(18)30459-8
  109. 2017, Future and potential spending on health 2015–40: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries, Lancet, 389, 2005, 10.1016/S0140-6736(17)30873-5 · DOI · Paper page
  110. Heller, 2006, The prospects of creating ‘fiscal space’ for the health sector, Health Policy Plan, 21, 75, 10.1093/heapol/czj013 · DOI
  111. Atun, 2012, Innovative financing for health: what is truly innovative?, Lancet, 380, 2044, 10.1016/S0140-6736(12)61460-3 · DOI
  112. Atun, 2017, Innovative financing instruments for global health 2002-15: a systematic analysis, Lancet Glob Health, 5, e720, 10.1016/S2214-109X(17)30198-5 · DOI
  113. Adeyi, 2009, Innovating for impact: the Affordable Medicines Facility-malaria (AMFm), Nat Med, 15, 991, 10.1038/nm0909-991b · DOI
  114. Adeyi, 2010, Universal access to malaria medicines: innovation in financing and delivery, Lancet, 376, 1869, 10.1016/S0140-6736(10)61189-0 · DOI
  115. Lin, 2016, Surveillance and response of hepatitis B virus in Hong Kong Special Administrative Region, 1988–2014, Western Pac Surveill Response J, 7, 24, 10.5365/wpsar.2015.6.3.003 · doi:10.5365/wpsar.2015.6.3.003
  116. Lao, 2014, Age-specific prevalence of hepatitis B virus infection in young pregnant women, Hong Kong Special Administrative Region of China, Bull World Health Organ, 92, 782, 10.2471/BLT.13.133413 · DOI
  117. Takahashi, 2012, The relevance of Japan's hepatitis vaccine policy to national Hepatitis B prevention and control, J Public Health Policy, 33, 136, 10.1057/jphp.2011.53 · doi:10.1057/jphp.2011.53
  118. Mahtab, 2008, Epidemiology of hepatitis B virus in Bangladeshi general population, Hepatobiliary Pancreat Dis Int, 7, 595
  119. Cui, 2013, Update on epidemiology of hepatitis B and C in China, J Gastroenterol Hepatol, 28, 7, 10.1111/jgh.12220 · doi:10.1111/jgh.12220
  120. Cui, 2017, Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China, Emerg Infect Dis, 23, 765, 10.3201/eid2305.161477 · DOI · Paper page
  121. Wang, 2017, No response to hepatitis B vaccine in infants born to HBsAg(+) mothers is associated to the transplacental transfer of HBsAg, Infect Dis, 49, 576, 10.1080/23744235.2017.1292541 · doi:10.1080/23744235.2017.1292541
  122. Xin, 2016, Seroepidemiological survey of hepatitis B virus infection among 764,460 women of childbearing age in rural China: a cross-sectional study, J Clin Virol, 81, 47, 10.1016/j.jcv.2016.05.014 · DOI
  123. Fan, 2016, A hepatitis B-free generation in China: from dream to reality, Lancet Infect Dis, 16, 1103, 10.1016/S1473-3099(16)30327-9 · doi:10.1016/s1473-3099(16)30327-9
  124. Hou, 2018, Management algorithm for interrupting mother to child transmission of hepatitis B virus, Clin Gastroenterol Hepatol
  125. Hou, 2017, Guideline of prevention and treatment for chronic hepatitis B (2015 update), J Clin Transl Hepatol, 5, 297, 10.14218/JCTH.2016.00019 · DOI · Paper page
  126. Altaf, 2013, Lessons learned from a communitybased intervention to improve injection safety in Pakistan, BMC Res Notes, 6, 159, 10.1186/1756-0500-6-159 · doi:10.1186/1756-0500-6-159
  127. Huang, 2016, Survey of hepatitis B knowledge and stigma among chronically infected patients and uninfected persons in Beijing, China, Liver Int, 36, 1595, 10.1111/liv.13168 · DOI
  128. Nelson, 2011, Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews, Lancet, 378, 571, 10.1016/S0140-6736(11)61097-0 · DOI · Paper page
  129. Ahmed, 2013, Population-attributable estimates for risk factors associated with hepatitis B and C: policy implications for Pakistan and other South Asian countries, Hepatol Int, 7, 500, 10.1007/s12072-012-9417-9 · doi:10.1007/s12072-012-9417-9
  130. Puri, 2014, Consensus statement of HCV task force of the Indian National Association for Study of the Liver (INASL). Part I: status report of HCV infection in India, J Clin Exp Hepatol, 4, 106, 10.1016/j.jceh.2014.05.006 · DOI
  131. Ali, 2009, Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors, Int J Infect Dis, 13, 9, 10.1016/j.ijid.2008.06.019 · DOI · Paper page
  132. Baatarkhuu, 2017, Acute hepatitis A, B and C but not D is still prevalent in Mongolia: a time trend analysis, Clin Mol Hepatol, 23, 147, 10.3350/cmh.2016.0055 · DOI
  133. Dhiman, 2014, Future of therapy for Hepatitis C in India: a matter of accessibility and affordability?, J Clin Exp Hepatol, 4, 85, 10.1016/j.jceh.2014.06.011 · DOI
  134. Lim, 2015, Reimbursement policies in the Asia-Pacific for chronic hepatitis B, Hepatol Int, 9, 43, 10.1007/s12072-014-9593-x · DOI
  135. Sekher TV. Catastrophic health expenditure and poor in India: health insurance is the answer? Proceedings of the 27th IUSSP International Population Conference 2013; 2013.
  136. Park, 2013, Determinants of suboptimal hepatitis B vaccine uptake among men in the Republic of Korea: where should our efforts be focused: results from cross-sectional study, BMC Infect Dis, 13, 218, 10.1186/1471-2334-13-218 · doi:10.1186/1471-2334-13-218
  137. Thio, 2015, Global elimination of mother-to-child transmission of hepatitis B: revisiting the current strategy, Lancet Infect Dis, 15, 981, 10.1016/S1473-3099(15)00158-9 · doi:10.1016/s1473-3099(15)00158-9
  138. Daw, 2016, Hepatitis C virus in North Africa: an emerging threat, Scientific World J, 2016, 7370524, 10.1155/2016/7370524 · doi:10.1155/2016/7370524
  139. Fadlalla, 2015, The epidemiology of hepatitis C virus in the Maghreb region: systematic review and meta-analyses, PLoS One, 10, e0121873, 10.1371/journal.pone.0121873 · doi:10.1371/journal.pone.0121873
  140. El-Sayed, 2015, Global estimate of HCV infection in the pediatric and adolescent population, J Hepatol, 62, S831, 10.1016/S0168-8278(15)31458-6 · doi:10.1016/s0168-8278(15)31458-6
  141. Rao, 2002, Further evidence for association of hepatitis C infection with parenteral schistosomiasis treatment in Egypt, BMC Infect Dis, 2, 29, 10.1186/1471-2334-2-29 · DOI
  142. Paez Jimenez, 2009, Injection drug use is a risk factor for HCV infection in urban Egypt, PLoS One, 4, e7193, 10.1371/journal.pone.0007193 · DOI
  143. Mohsen, 2015, Hepatitis C virus acquisition among Egyptians: analysis of a 10-year surveillance of acute hepatitis C, Trop Med Int Health, 20, 89, 10.1111/tmi.12410 · DOI
  144. El-Akel, 2017, National treatment programme of hepatitis C in Egypt: hepatitis C virus model of care, J Viral Hepat, 24, 262, 10.1111/jvh.12668 · DOI · Paper page
  145. Waked, 2014, The current and future disease burden of chronic hepatitis C virus infection in Egypt, Arab J Gastroenterol, 15, 45, 10.1016/j.ajg.2014.04.003 · DOI
  146. Donald, 2015, Curing hepatitis C, in an experiment the size of Egypt, The New York Times
  147. Doss, 2016, Real-life results of sofosbuvir based therapy for Egyptian patients with hepatitis C and advanced fibrosis-cirrhosis, J Hepatol, 64, S772, 10.1016/S0168-8278(16)01505-1 · doi:10.1016/s0168-8278(16)01505-1
  148. Esmat, 2018, Further steps to elimination of hepatitis C in Egypt, Lancet Gastroenterol Hepatol, 3, 665, 10.1016/S2468-1253(18)30268-1 · doi:10.1016/s2468-1253(18)30268-1
  149. 2012, Progress toward prevention and control of hepatitis C virus infection—Egypt, 2001–2012, MMWR Morb Mortal Wkly Rep, 61, 545
  150. Al-Faleh, 1988, Hepatitis B infection in Saudi Arabia, Ann Saudi Med, 8, 474, 10.5144/0256-4947.1988.474 · doi:10.5144/0256-4947.1988.474
  151. Abdo, 2012, Epidemiology of viral hepatitis in Saudi Arabia: are we off the hook?, Saudi J Gastroenterol, 18, 349, 10.4103/1319-3767.103425 · DOI
  152. Abdo, 2012, Epidemiology of viral hepatitis in Saudi Arabia: are we off the hook?, Saudi J Gastroenterol, 18, 349, 10.4103/1319-3767.103425 · DOI
  153. Abaalkhail, 2014, SASLT practice guidelines for the management of hepatitis B virus, Saudi J Gastroenterol, 20, 5, 10.4103/1319-3767.126311 · DOI
  154. Al-Faleh, 1999, Seroepidemiology of hepatitis B virus infection in Saudi children 8 years after a mass hepatitis B vaccination programme, J Infect, 38, 167, 10.1016/S0163-4453(99)90245-1 · DOI
  155. Al-Faleh, 2008, Long-term protection of hepatitis B vaccine 18 years after vaccination, J Infect, 57, 404, 10.1016/j.jinf.2008.08.008 · DOI
  156. Denniston, 2014, Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010, Ann Intern Med, 160, 293, 10.7326/M13-1133 · DOI · Paper page
  157. Pereira, 2013, Prevalence and risk factors of hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional study, BMC Infect Dis, 13, 60, 10.1186/1471-2334-13-60 · DOI · Paper page
  158. Ferreira, 2015, Disease burden of chronic hepatitis C in Brazil, Braz J Infect Dis, 19, 363, 10.1016/j.bjid.2015.04.004 · doi:10.1016/j.bjid.2015.04.004
  159. Kikuchi, 2013, Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil, Antivir Ther, 18, 445, 10.3851/IMP2602 · doi:10.3851/imp2602
  160. Ropero Álvarez, 2017, Progress in vaccination towards hepatitis B control and elimination in the region of the Americas, BMC Public Health, 17, 325, 10.1186/s12889-017-4227-6 · doi:10.1186/s12889-017-4227-6
  161. Heyward, 1985, The control of hepatitis B virus infection with vaccine in Yupik Eskimos. Demonstration of safety, immunogenicity, and efficacy under field conditions, Am J Epidemiol, 121, 914, 10.1093/oxfordjournals.aje.a114061 · DOI
  162. Cabezas, 2000, [Impact of the Immunization Program Integrated to the Expanded Immunization Program(Epi) in Huanta,1994-1997], Rev Gastroenterol Peru, 20, 201
  163. de la Hoz, 2008, Eight years of hepatitis B vaccination in Colombia with a recombinant vaccine: factors influencing hepatitis B virus infection and effectiveness, Int J Infect Dis, 12, 183, 10.1016/j.ijid.2007.06.010 · DOI
  164. Patrick, 2003, Elimination of acute hepatitis B among adolescents after one decade of an immunization programme targeting grade 6 students, Pediatr Infect Dis J, 22, 874, 10.1097/01.inf.0000091291.14317.dc · DOI
  165. Souto, 2016, Distribution of hepatitis B infection in Brazil: the epidemiological situation at the beginning of the 21st century, Rev Soc Bras Med Trop, 49, 11, 10.1590/0037-8682-0176-2015 · DOI
  166. Viana, 2005, High prevalence of hepatitis B virus and hepatitis D virus in the western Brazilian Amazon, Am J Trop Med Hyg, 73, 808, 10.4269/ajtmh.2005.73.808 · doi:10.4269/ajtmh.2005.73.808
  167. Fan, 2016, Cost-effectiveness of active-passive prophylaxis and antiviral prophylaxis during pregnancy to prevent perinatal hepatitis B virus infection, Hepatology, 63, 1471, 10.1002/hep.28310 · DOI
  168. Terrault, 2016, AASLD guidelines for treatment of chronic hepatitis B, Hepatology, 63, 261, 10.1002/hep.28156 · DOI · Paper page
  169. Jonas, 2016, Streamlining screening to treatment: the hepatitis C cascade of care at Kaiser Permanente mid-Atlantic states, Clin Infect Dis, 62, 1290, 10.1093/cid/ciw086 · doi:10.1093/cid/ciw086
  170. Sidlow, 2015, Improving hepatitis C virus screening rates in primary care: a targeted intervention using the electronic health record, J Healthc Qual, 37, 319, 10.1097/JHQ.0000000000000010 · doi:10.1097/jhq.0000000000000010
  171. Shah, 2018, The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver, CMAJ, 190, e677, 10.1503/cmaj.170453 · DOI
  172. Mehta, 2011, Changes in blood-borne infection risk among injection drug users, J Infect Dis, 203, 587, 10.1093/infdis/jiq112 · DOI
  173. Skarupski, 2018, The health of America's aging prison population, Epidemiol Rev, 40, 157, 10.1093/epirev/mxx020 · DOI · Paper page
  174. He, 2016, Prevention of hepatitis C by screening and treatment in U.S. prisons, Ann Intern Med, 164, 84, 10.7326/M15-0617 · DOI · Paper page
  175. Spaulding, 2012, Screening for HCV infection in jails, JAMA, 307, 1259, 10.1001/jama.2012.374 · DOI
  176. Canary, 2017, Geographic disparities in access to syringe services programs among young persons with hepatitis C virus infection in the United States, Clin Infect Dis, 65, 514, 10.1093/cid/cix333 · DOI
  177. Mendes, 2016, Loss to follow-up in anti-HCV-positive patients in a Brazilian regional outpatient clinic, Braz J Med Biol Res, 49, e5455, 10.1590/1414-431x20165455 · doi:10.1590/1414-431x20165455
  178. Gowda, 2018, Absolute insurer denial of direct-acting antiviral therapy for hepatitis C: a national specialty pharmacy cohort study, Open Forum Infect Dis, 5, ofy076, 10.1093/ofid/ofy076 · DOI
  179. Foster, 2016, Awareness of infection and medical follow-up among persons testing positive for hepatitis C virus—National Health and Nutrition Examination Survey, 2001–2014, Open Forum Infect Dis, 3, 1787, 10.1093/ofid/ofw194.145 · DOI
  180. Mitchell, 2011, The increasing burden of imported chronic hepatitis B—United States, 1974-2008, PLoS One, 6, e27717, 10.1371/journal.pone.0027717 · DOI
  181. Soto-Ramirez, 2017, World hepatitis day. Fighting hepatitis C in Latin America and the Caribbean; an urgent call, J Int AIDS Soc, 20, 22183, 10.7448/IAS.20.1.22183 · doi:10.7448/ias.20.1.22183
  182. Razavi, 2017, Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study, Lancet Gastroenterol Hepatol, 2, 325, 10.1016/S2468-1253(17)30045-6 · DOI · Paper page
  183. Degenhardt, 2016, Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013, Lancet Infect Dis, 16, 1385, 10.1016/S1473-3099(16)30325-5 · DOI · Paper page
  184. Papatheodoridis, 2018, Hepatitis C: the beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe, J Viral Hepat, 25, 6, 10.1111/jvh.12875 · doi:10.1111/jvh.12875
  185. Platt, 2016, Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis, Lancet Infect Dis, 16, 797, 10.1016/S1473-3099(15)00485-5 · DOI · Paper page
  186. Berenguer, 2018, Human immunodeficiency virus/hepatitis C virus coinfection in Spain: elimination is feasible, but the burden of residual cirrhosis will be significant, Open Forum Infect Dis, 5, ofx258, 10.1093/ofid/ofx258 · doi:10.1093/ofid/ofx258
  187. Peters, 2014, HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective, BMC Infect Dis, 14, S13, 10.1186/1471-2334-14-S6-S13 · doi:10.1186/1471-2334-14-s6-s13
  188. Rockstroh, 2018, Is hepatitis C virus elimination in well-defined patient groups possible?, Clin Infect Dis, 66, 1366, 10.1093/cid/cix1010 · DOI
  189. Innes, 2017, The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen, J Hepatol, 10.1016/S0168-8278(17)30306-9 · doi:10.1016/s0168-8278(17)30306-9
  190. Hutchinson, 2018, Reduction in the incidence of hepatitis C related decompensated cirrhosis associated with national scale-up of DAA therapies targeting patients with advanced liver fibrosis, J Hepatol, 68, S67, 10.1016/S0168-8278(18)30355-6 · doi:10.1016/s0168-8278(18)30355-6
  191. Foster, 2016, Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis, J Hepatol, 64, 1224, 10.1016/j.jhep.2016.01.029 · DOI · Paper page
  192. Falla, 2018, Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups, BMC Infect Dis, 18, 79, 10.1186/s12879-018-2988-x · DOI
  193. Edmunds, 1993, The influence of age on the development of the hepatitis B carrier state, Proc Biol Sci, 253, 197, 10.1098/rspb.1993.0102 · DOI · Paper page
  194. Hahné, 2013, Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening, BMC Infect Dis, 13, 181, 10.1186/1471-2334-13-181 · DOI · Paper page
  195. Spina, 2014, Policy responses to viral hepatitis B and C among people who inject drugs in Member States of the WHO European region: a sub-analysis of the WHO 2013 global hepatitis policy survey, BMC Infect Dis, 14, S15, 10.1186/1471-2334-14-S6-S15 · DOI
  196. Mora, 2016, A synthesis of hepatitis C prevalence estimates in sub-Saharan Africa: 2000–2013, BMC Infect Dis, 16, 283, 10.1186/s12879-016-1584-1 · doi:10.1186/s12879-016-1584-1
  197. Rao, 2015, Hepatitis C seroprevalence and HIV co-infection in sub-Saharan Africa: a systematic review and meta-analysis, Lancet Infect Dis, 15, 819, 10.1016/S1473-3099(15)00006-7 · DOI
  198. Umoh, 2011, Aetiological differences in demographical, clinical and pathological characteristics of hepatocellular carcinoma in The Gambia, Liver Int, 31, 215, 10.1111/j.1478-3231.2010.02418.x · DOI
  199. Gupta, 2017, “Waiting for direct-acting antivirals”: a retrospective chart review of patients with untreated hepatitis C in Rwanda, PLoS One, 12, e0174148, 10.1371/journal.pone.0174148 · doi:10.1371/journal.pone.0174148
  200. Gupta, 2018, Is hepatitis C elimination possible in sub-Saharan Africa? The case of Rwanda, Lancet Gastroenterol Hepatol, 3, 302, 10.1016/S2468-1253(18)30089-X · doi:10.1016/s2468-1253(18)30089-x

200 of 253 shown

Cited by

See all 535

Metadata

Authors
Cooke, G. S., Andrieux-Meyer, I., Applegate, T. L., Atun, R., Burry, J. R., Cheinquer, H., Dusheiko, G., Feld, J. J., Gore, C., Griswold, M. G., Hamid, S., Hellard, M. E., Hou, J., Howell, J., Jia, J., Kravchenko, N., Lazarus, J. V., Lemoine, M., Lesi, O. A., Maistat, L., McMahon, B. J., Razavi, H., Roberts, T., Simmons, B., Sonderup, M. W., Spearman, C. W., Taylor, B. E., Thomas, D. L., Waked, I., Ward, J. W., Wiktor, S. Z., Abdo, A., Aggarwal, R., Aghemo, A., Al-Judaibi, B., Al Mahtab, M., Altaf, A., Ameen, Z., Asselah, T., Baatarkkhuu, O., Barber, E., Barnes, E., Boulet, P., Burrows, L., Butsashvili, M., Chan, E., Chow, C., Cowie, B., Cunningham, C., de Araujo, A., Diap, G., Dore, G., Doyle, J., Elsayed, M., Fajardo, E., Gane, E., Getahun, A., Goldberg, D., Got, T., Hickman, M., Hill, A., Hutchinson, S., Jones, C., Kamili, S., Khan, A., Lee, A., Lee, T. Y., Malani, J., Morris, T. M., Nayagam, S., Njouom, R., Ocama, P., Pedrana, A., Peeling, R., Reddy, A., Sacks, J., Sarin, S., Shimakawa, Y., Silva, M., Skala, P., Taylor-Robinson, S., Thompson, A., Thursz, M., Tonganibeia, A., Wallace, J., Ward, J., Wolff, F., Vickerman, P., & Yau, J.
Venue
The Lancet Gastroenterology & Hepatology
Publisher
Elsevier BV
Published
2019-02
Volume
4
Issue
2
Pages
135-184
ISSN
  • 2468-1156 (ISSN-L)
  • 2468-1253
DOI
10.1016/s2468-1253(18)30270-x
OpenAlex
W2909795031
Cited by
535
References
9
FWCI
40.94
Type
journal article
Language
en
Update notices
erratum (2019-05-01)
Open access
green
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
  • World Health Organization (293)
  • National Institute for Health and Care Research

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. https://app.cochat.ai/papers/10.1016/s2468-1253(18)30270-x
The paper
Cooke, G. S., Andrieux-Meyer, I., Applegate, T. L., Atun, R., Burry, J. R., Cheinquer, H., Dusheiko, G., Feld, J. J., Gore, C., Griswold, M. G., Hamid, S., Hellard, M. E., Hou, J., Howell, J., Jia, J., Kravchenko, N., Lazarus, J. V., Lemoine, M., Lesi, O. A., . . . Yau, J. (2019). Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. The Lancet Gastroenterology & Hepatology. https://doi.org/10.1016/s2468-1253(18)30270-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.